Literature DB >> 26276359

Association of GRM4 gene polymorphisms with susceptibility and clinicopathological characteristics of osteosarcoma in Guangxi Chinese population.

Kun Wang1,2, Jinmin Zhao2,3, Maolin He4,5, Mitra Fowdur1,2, Tenglong Jiang1,2, Shuju Luo1,2.   

Abstract

Osteosarcoma is the most frequent malignant primary bone tumor. GRM4 is expressed in human osteosarcoma cells, and high expression of mGluR4 in osteosarcoma tissues is related to poor prognosis. The aim of this study was to investigate the association between polymorphism of the GRM4 gene and the susceptibility to osteosarcoma in a Chinese population. In a case-control study, we investigated polymorphisms in the GRM4 gene (rs2229901, rs733457, and rs1906953) with a real-time quantitative polymerase chain reaction (PCR) assay (TaqMan). The study was conducted with 126 Chinese patients with osteosarcoma and 168 Chinese subjects in a control group. Unconditional logistic regression was used to analyze the correlation between single nucleotide polymorphisms (SNPs) and osteosarcoma risk. Different survival rates of different genotypic patients with osteosarcoma were analyzed through Kaplan-Meier. There were statistically significant differences in the distributions of the rs1906953 genotypes between the cases and control group (P = 0.034). However, there was no remarkable difference in the three genotypes of GRM4 gene rs2229901 locus between the patient group and control group (P = 0.369). Survival analysis for rs1906953 showed that the median survival time of osteosarcoma patients with the CC genotype was significantly shorter compared to the CT and TT genotypes; patients carrying CC genotype have apparently got a decrease in their recurrence-free survival time in comparison with patients carrying TT genotype. Our data suggest that GRM4 gene polymorphism is closely related to the morbidity and metastasis of osteosarcoma in a Chinese population.

Entities:  

Keywords:  Clinicopathological characteristics; GRM4; Osteosarcoma; Single nucleotide polymorphism

Mesh:

Substances:

Year:  2015        PMID: 26276359     DOI: 10.1007/s13277-015-3904-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  32 in total

1.  Association study of polymorphisms in the group III metabotropic glutamate receptor genes, GRM4 and GRM7, with schizophrenia.

Authors:  Hiroki Shibata; Ayako Tani; Tomoyuki Chikuhara; Rumiko Kikuta; Mayumi Sakai; Hideaki Ninomiya; Nobutada Tashiro; Nakao Iwata; Norio Ozaki; Yasuyuki Fukumaki
Journal:  Psychiatry Res       Date:  2009-04-07       Impact factor: 3.222

Review 2.  The role of glutamate in the regulation of bone mass and architecture.

Authors:  T M Skerry
Journal:  J Musculoskelet Neuronal Interact       Date:  2008 Apr-Jun       Impact factor: 2.041

3.  A transgenic mouse bearing an antisense construct of regulatory subunit type 1A of protein kinase A develops endocrine and other tumours: comparison with Carney complex and other PRKAR1A induced lesions.

Authors:  K J Griffin; L S Kirschner; L Matyakhina; S G Stergiopoulos; A Robinson-White; S M Lenherr; F D Weinberg; E S Claflin; D Batista; I Bourdeau; A Voutetakis; F Sandrini; E M Meoli; A J Bauer; Y S Cho-Chung; S R Bornstein; J A Carney; C A Stratakis
Journal:  J Med Genet       Date:  2004-12       Impact factor: 6.318

4.  Pharmacological activation of mGlu4 metabotropic glutamate receptors inhibits the growth of medulloblastomas.

Authors:  Luisa Iacovelli; Antonietta Arcella; Giuseppe Battaglia; Simonetta Pazzaglia; Eleonora Aronica; Paola Spinsanti; Alessandra Caruso; Enrico De Smaele; Anna Saran; Alberto Gulino; Mara D'Onofrio; Felice Giangaspero; Ferdinando Nicoletti
Journal:  J Neurosci       Date:  2006-08-09       Impact factor: 6.167

5.  Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice.

Authors:  Sam D Molyneux; Marco A Di Grappa; Alexander G Beristain; Trevor D McKee; Daniel H Wai; Jana Paderova; Meenakshi Kashyap; Pingzhao Hu; Tamara Maiuri; Swami R Narala; Vuk Stambolic; Jeremy Squire; Josef Penninger; Otto Sanchez; Timothy J Triche; Geoffrey A Wood; Lawrence S Kirschner; Rama Khokha
Journal:  J Clin Invest       Date:  2010-08-09       Impact factor: 14.808

6.  Association of FGFR3 and MDM2 gene nucleotide polymorphisms with bone tumors.

Authors:  V A Naumov; E V Generozov; Yu N Solovyov; M D Aliev; N E Kushlinsky
Journal:  Bull Exp Biol Med       Date:  2012-10       Impact factor: 0.804

7.  Signal transduction and pharmacological characteristics of a metabotropic glutamate receptor, mGluR1, in transfected CHO cells.

Authors:  I Aramori; S Nakanishi
Journal:  Neuron       Date:  1992-04       Impact factor: 17.173

8.  The glutamatergic system expression in human PC-3 and LNCaP prostate cancer cells.

Authors:  Nikolaos Pissimissis; Efstathia Papageorgiou; Peter Lembessis; Athanasios Armakolas; Michael Koutsilieris
Journal:  Anticancer Res       Date:  2009-01       Impact factor: 2.480

9.  Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study.

Authors:  Daniela Caronia; Ana Patiño-Garcia; Antonio Peréz-Martínez; Guillermo Pita; Leticia Tais Moreno; Marta Zalacain-Díez; Blanca Molina; Isabel Colmenero; Luis Sierrasesúmaga; Javier Benítez; Anna Gonzalez-Neira
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

10.  Lysyl oxidase polymorphisms and susceptibility to osteosarcoma.

Authors:  Yang Liu; Bitao Lv; Zhimin He; Yujia Zhou; Carrie Han; Guodong Shi; Rui Gao; Ce Wang; Lili Yang; Haihan Song; Wen Yuan
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.752

View more
  6 in total

1.  Common genetic variation and risk of osteosarcoma in a multi-ethnic pediatric and adolescent population.

Authors:  Chenan Zhang; Helen M Hansen; Eleanor C Semmes; Julio Gonzalez-Maya; Libby Morimoto; Qingyi Wei; William C Eward; Suzanne B DeWitt; Jillian H Hurst; Catherine Metayer; Adam J de Smith; Joseph L Wiemels; Kyle M Walsh
Journal:  Bone       Date:  2019-09-13       Impact factor: 4.398

Review 2.  Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact.

Authors:  Claudia Maria Hattinger; Maria Pia Patrizio; Silvia Luppi; Massimo Serra
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

Review 3.  Genomic Predictors of Asthma Phenotypes and Treatment Response.

Authors:  Natalia Hernandez-Pacheco; Maria Pino-Yanes; Carlos Flores
Journal:  Front Pediatr       Date:  2019-02-05       Impact factor: 3.418

4.  Genome-wide association and evolutionary analyses reveal the formation of swine facial wrinkles in Chinese Erhualian pigs.

Authors:  Tao Huang; Mingpeng Zhang; Guorong Yan; Xiaochang Huang; Hao Chen; Liyu Zhou; Wenjiang Deng; Zhen Zhang; Hengqing Qiu; Huashui Ai; Lusheng Huang
Journal:  Aging (Albany NY)       Date:  2019-07-15       Impact factor: 5.682

5.  Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis.

Authors:  Clara Benna; Andrea Simioni; Sandro Pasquali; Davide De Boni; Senthilkumar Rajendran; Giovanna Spiro; Chiara Colombo; Calogero Virgone; Steven G DuBois; Alessandro Gronchi; Carlo Riccardo Rossi; Simone Mocellin
Journal:  Oncotarget       Date:  2018-04-06

6.  Glutamate metabotropic receptor 4 (GRM4) inhibits cell proliferation, migration and invasion in breast cancer and is regulated by miR-328-3p and miR-370-3p.

Authors:  Bin Xiao; Daxiang Chen; Quan Zhou; Jianfeng Hang; Weiyun Zhang; Zhenzhan Kuang; Zhaohui Sun; Linhai Li
Journal:  BMC Cancer       Date:  2019-09-06       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.